Top Stories
Personalized Cancer Vaccine Shows Promise In Major Trial
Pharmaceutical companies Merck and Moderna reported that an experimental personalized mRNA vaccine, given alongside the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone.
Read more at DAILY WIRE ›
Read the full story at
DAILY WIRE
The Gadsden Report aggregates and summarises headlines. The reporting above belongs to DAILY WIRE, and the link opens their page. This page exists so readers can find, share, and discuss the story here.